Risk of cervical cancer associated with extending the interval between cervical-cancer screenings

New England Journal of Medicine

Volumn 349, Issue 16, 2003, Pages 1501-1509

  Sawaya, George F ^a   McConnell, K John ^a,c   Kulasingam, Shalini L ^d   Lawson, Herschel W ^f   Kerlikowske, Karla ^a,b   Melnikow, Joy ^e   Lee, Nancy C ^f   Gildengorin, Ginny ^a   Myers, Evan R ^d   Washington, A Eugene ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; DYSPLASIA; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SOCIOECONOMICS; UTERINE CERVIX CANCER; ADOLESCENT; MASS SCREENING; MIDDLE AGED; RISK; SENSITIVITY AND SPECIFICITY; TIME; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0141940149     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035419     Document Type: Article

References (47)

1. Cervical cancer-screening. Rockville, Md.: Preventive Services Task Force, 2003. (Accessed September 19, 2003, at http://www.ahrq.gov/clinic/uspstf/uspscerv.htm.)
2. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
3. Fink DJ. Change in American Cancer Society Checkup Guidelines for detection of cervical cancer. CA Cancer J Clin 1988;38: 127-8.
4. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003; 348:489-90.
5. Myers ER, McCrory DC, Subramanian S, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol 2000;96:645-52.
6. Henson RM, Wyatt SW, Lee NC. The National Breast and Cervical Cancer Early Detection Program: a comprehensive public health response to two major health issues for women. J Public Health Manage Pract 1996;2:36-47.
7. Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol 2000;96:219-23.
8. Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. Obstet Gynecol 1998;92:745-52.
9. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology: the 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-9.
10. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:64.
11. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
12. Evaluation of cervical cytology. Evidence report/technology assessment. No. 5. Rockville, Md.: Agency for Health Care Policy and Research, February 1999. (AHCPR publication no. 99-E010.)
13. Duggan MA, McGregor SE, Stuart GC, et al. The natural history of CIN I lesions. Eur J Gynaecol Oncol 1998;19:338-44.
14. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
15. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35.
16. van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65.
17. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 1992;79:675-82.
18. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
19. Munoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:504-10.
20. Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 1992;117:520-7.
21. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990;113:214-26.
22. Schwartz PE, Hadjimichael O, Lowell DM, Merino MJ, Janerich D. Rapidly progressive cervical cancer: the Connecticut experience. Am J Obstet Gynecol 1996;175: 1105-9.
23. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health 1995;85:791-4.
24. Bearman DM, MacMillan JP, Creasman WT. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol 1987;69:151-5. [Erratum, Obstet Gynecol 1987;69:660.]
25. Bearman DM, MacMillan JP, Creasman WT. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol 1987;69:151-5. [Erratum, Obstet Gynecol 1987;69:660.]
26. Pretorius R, Semrad N, Watring W, Fotheringham N. Presentation of cervical cancer. Gynecol Oncol 1991;42:48-53.
27. Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER cancer statistics review, 1975-2000. Bethesda, Md.: National Cancer Institute, 2003. (Also available at http://seer.cancer./gov/csr/1975_2000.)
28. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
29. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
30. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283: 87-93.
31. Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-6.
32. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001;83:439-44. [Erratum, Gynecol Oncol 2002;84:355.]
33. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001;83:439-44. [Erratum, Gynecol Oncol 2002;84:355.]
34. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288:1749-57.
35. Stenkvist B, Soderstrom J. Reasons for cervical cancer despite extensive screening. J Med Screen 1996;3:204-7.
36. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
37. Hutchinson ML, Zahniser DJ, Sherman ME, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999;87:48-55.
38. Payne N, Chilcott J, McGoogan E. Liquid-based cytology in cervical screening. Sheffield, England: School of Health and Related Research, University of Sheffield, 2000.
39. Devesa SS, Young JL Jr, Brinton LA, Fraumeni JF Jr. Recent trends in cervix uteri cancer. Cancer 1989;64:2184-90.
40. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after 3 decades of screening US women under age 30 years. Obstet Gynecol (in press).
41. Cervical cancer. NIH consensus statement online. Bethesda, Md.: National Institutes of Health, April 1996. (Accessed September 19, 2003, at http://consensus.nih.gov/cons/102/102_statement.htm.)
42. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528-40.
43. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999;94:307-10.
44. Sawaya GF, Brown AD, Washington AE, Garber AM. Current approaches to cervical-cancer screening. N Engl J Med 2001;344: 1603-7.
45. Sawaya GF, Grady D, Kerlikowske K, et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement study (HERS). Ann Intern Med 2000;133:942-50.
46. Freeman-Wang T, Walker P, Linehan J, Coffey C, Glasser B, Sherr L. Anxiety levels in women attending colposcopy clinics for treatment for cervical intraepithelial neoplasia: a randomised trial of written and video information. BJOG 2001;108:482-4.
47. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.